Clinical Pharmacology of Itraconazole in Children and Adolescents

Autor:	Efi Drogouti, Georg Hempel, Andeas Groll, Zoe Dorothea Pana, Athanasios Tragiannidis
Rok vydání:	2015
Předmět:	Antifungal medicine.medical_specialty Clinical pharmacology Itraconazole medicine.drug_class business.industry Drug molecule Dermatology law.invention Broad spectrum Infectious Diseases law medicine Intensive care medicine business medicine.drug
Zdroj:	Current Fungal Infection Reports. 9:65-73
ISSN:	1936-377X 1936-3761
DOI:	10.1007/s12281-015-0218-1
Popis:	Invasive fungal infections are recognized as life-threatening complications primarily in immunocompromised patients, including children with primary immunodeficiencies and hematological malignancies. The antifungal triazoles have become extremely useful components of the antifungal armamentarium. They are well tolerated and possess a broad spectrum of activity. Itraconazole was discovered in 1984 and became available for clinical use in 1990. Itraconazole is a broad spectrum, triazole antifungal agent, and class II drug molecule with low solubility and high permeability and several indications in adults. This article provides a brief overview of the pharmacology of itraconazole with focus on the available data in immunocompromised children and adolescents.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::53c5e079a52f5f527d1fa9e898fc374c https://doi.org/10.1007/s12281-015-0218-1 Zobrazit plný text záznamu Full text from SpringerLink